



July 31, 2008

Kyowa Hakko Kogyo Co., Ltd.

Appendix to the Consolidated Financial Statements

First quarter results for Fiscal 2008

(April 1, 2008 - June 30, 2008)

	Contents	Page
Consolidated	I. Financial results	
	1. Income	1
	2. Results by segment	1
	3. Other income	2
	4. Extraordinary income/losses	2
	5. R&D expenses	2
	6. Capital expenditure	3
	7. Depreciation expenses	3
	8. Key indicators	3
	II. Subsidiaries and affiliates	4
Non-Consolidated	III. Financial results	
	Net sales by division	5
	R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the first quarter of the fiscal year ending March 31, 2009. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts

1. Trends in Consolidated Financial Results

*Forecasts for the fiscal year ending March 31, 2009 have not changed from those announced on April 28, 2008

1. Trends in income

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Apr. 2007 to Jun. 30, 2007 (A)	Interim results	Full year results	Apr. 1, 2008 to Jun. 30, 2008 (B)	First quarter comparison		Interim forecast	Full year forecast
				Amount change (B-A)	Percentage change			
Net sales	94,978	192,639	392,119	125,435	30,457	132%	245,000	490,000
Gross Profit	36,528	72,116	144,917	58,843	22,315	161%		
Selling, general and administrative expenses	28,960	53,869	105,527	41,770	12,810	144%		
Operating income (prior to amortization of goodwill)				19,471			35,850	66,700
Operating income	7,568	18,246	39,390	17,072	9,504	226%	31,000	57,000
Other income	1,944	2,521	4,863	2,772	827			
Other expenses	1,139	2,687	6,257	1,049	(90)			
Recurring income	8,372	18,080	37,996	18,795	10,422	224%	31,000	56,000
Extraordinary income	328	328	7,988	--	(328)			
Extraordinary losses	--	406	7,169	1,523	1,523			
Net income before income taxes	8,701	18,002	38,815	17,272	8,571			
Corporate, local and enterprise taxes	2,209	7,125	15,228	6,769	4,560			
Corporate tax adjustment	1,134	(259)	(35)	746	(388)			
Income (loss) in minority interests	37	89	144	167	130			
Net income	5,319	11,047	23,477	9,588	4,268	180%	16,000	28,000
EPS before goodwill amortization ¥/share)			¥59.03	¥20.87				¥65.59

*Goodwill prior to amortization is the amount recorded prior to amortization of goodwill (Apr. to Jun. results: ¥2,399 million) following the reverse acquisition (share exchange with Kirin Pharma).

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Apr. 2007 to Jun. 30, 2007 (A)	Interim results	Full year results	Apr. 1, 2008 to Jun. 30, 2008 (B)	First quarter comparison		Interim forecast	Full year forecast
				Amount change (B-A)	Percentage change			
Net sales	94,978	192,639	392,119	125,435	30,457	132%	245,000	490,000
Pharmaceuticals	34,519	68,900	138,377	59,190	24,671	171%	111,000	214,000
Bio-Chemicals	22,434	43,808	86,820	22,944	509	102%	44,000	90,000
Chemicals	23,705	51,045	108,007	25,135	1,429	106%	55,000	116,000
Food	10,472	20,947	43,324	10,393	(79)	99%	21,000	43,000
Other	12,024	24,647	48,998	17,892	5,867	149%	34,000	67,000
Total	103,156	209,349	425,527	135,555	32,399	131%	265,000	530,000
Eliminations	(8,178)	(16,709)	(33,407)	(10,120)	(1,942)	124%	(20,000)	(40,000)
Operating income	7,568	18,246	39,390	17,072	9,504	226%	31,000	57,000
(Before goodwill amortization)				19,471			35,850	66,700
Pharmaceuticals (Before goodwill amortization)	3,023	9,733	19,961	12,851	9,827	425%	23,700	39,000
Bio-Chemicals (Before goodwill amortization)	2,011	4,045	9,688	2,972	960	148%	3,700	9,000
Chemicals (Before goodwill amortization)	1,883	3,275	7,169	509	(1,373)	27%	2,500	6,500
Food (Before goodwill amortization)	416	674	1,576	396	(19)	95%	600	1,500
Other (Before goodwill amortization)	168	456	838	273	104	162%	500	1,000
Total (Before goodwill amortization)	7,503	18,185	39,234	17,002	9,499	227%	31,000	57,000
Eliminations	64	61	155	69	5	108%	--	--

(2) Overseas sales

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008				April 1, 2008 to March 31, 2009			
	Apr. 2007 to Jun. 30, 2007	Percentage of consolidated sales	Interim results	Percentage of consolidated sales	Full year results	Percentage of consolidated sales	Apr. 1, 2008 to Jun. 30, 2008	Percentage of consolidated sales
Overseas sales	18,192	19.2%	39,604	20.6%	75,217	19.2%	31,711	25.3%
America	6,904	7.3%	15,154	7.9%	23,149	5.9%	15,859	12.6%
Europe	5,054	5.3%	10,417	5.4%	22,475	5.7%	6,720	5.4%
Asia	5,844	6.2%	13,780	7.2%	29,052	7.4%	8,981	7.2%
Other regions	389	0.4%	251	0.1%	539	0.1%	149	0.1%
Total consolidated net sales	94,978	100%	192,639	100.0%	392,119	100.0%	125,435	100.0%

3. Trends in other income

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009
	Apr. 1, 2007 to Jun. 30, 2007	Interim results	Full year results	Apr. 1, 2008 to Jun. 30, 2008
Other income	1,944	2,521	4,863	2,772
Interest income	109	225	528	185
Dividend income	676	743	1,274	574
Foreign exchange gain	428	--	--	1,388
Income from equity method investments	312	502	1,125	303
Other	417	1,050	1,935	319
Other expenses	1,139	2,687	6,257	1,049
Interest expense	86	171	327	190
Foreign exchange loss	--	307	1,034	--
Other	1,053	2,209	4,894	859

4. Trends in extraordinary income / losses

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009
	Apr. 1, 2007 to Jun. 30, 2007	Interim results	Full year results	Apr. 1, 2008 to Jun. 30, 2008
Extraordinary income	328	328	7,988	--
Gain on sale of fixed assets	328	328	7,471	--
Other income	--	--	517	--
Extraordinary losses	--	406	7,169	1,523
Asset impairment losses	--	--	2,264	1,308
Integration-related expenses	--	--	2,831	214
Loss from revaluation of investment in affiliates	--	--	1,372	--
Provisions for loss on guarantees	--	--	700	--

5. Trends in R&D expenses

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009			
	Apr. 1, 2007 to Jun. 30, 2007 (A)	Interim results	Full year results	Apr. 1, 2008 to Jun. 30, 2008 (B)	Amount change (B-A)	Interim forecasts	Full year forecasts
R&D (Consolidated)	11.3	18.8	34.1	14.3	2.9	25.2	52.2
R&D to net sales ratio (%)	11.9%	9.8%	8.7%	11.4%	(0.5%)	10.3%	10.7%
Pharmaceuticals	9.8	15.8	28.1	12.8	3.0	21.8	45.2
(R&D to net sales ratio) (%)	28.6%	23.0%	20.4%	21.7%	(6.8%)	19.7%	21.1%
Bio-Chemicals	0.9	1.9	3.9	0.9	(0.0)	2.1	4.4
Chemicals	0.2	0.5	1.0	0.3	0.0	0.7	1.5
Food	0.2	0.4	0.9	0.2	(0.0)	0.4	1.0
Other	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0

6. Trends in capital expenditure

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008		April 1, 2008 to March 31, 2009		
	Apr. 2007 to Sep. 2007	Full year results	Apr. 2008 to Jun. 2008	Interim forecasts	Full year forecasts
Capital expenditure (Consolidated)	7.7	14.7	3.8	11.2	28.8
Pharmaceuticals	1.4	4.2	1.4	5.2	15.8
Bio-Chemicals	2.0	4.1	0.8	1.6	6.7
Chemicals	2.5	4.3	1.4	3.9	5.4
Food	1.6	1.9	0.0	0.4	0.9
Other	0.0	0.0	0.0	0.0	0.0

7. Trends in depreciation expenses

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008		April 1, 2008 to March 31, 2009		
	Apr. 2007 to Sep. 2007	Full year results	Apr. 2008 to Jun. 2008	Interim forecasts	Full year forecasts
Depreciation expenses (Consolidated)	6.7	14.3	4.3	8.9	19.7
Pharmaceuticals	1.8	3.9	1.9	3.6	8.2
Bio-Chemicals	2.6	5.5	1.1	2.5	5.5
Chemicals	1.7	3.7	0.9	2.2	4.8
Food	0.4	0.9	0.2	0.5	1.0
Other	0.0	0.1	0.0	0.0	0.1

8. Trends in key indicators

(1) Exchange rate

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009		
	Apr. 2007 to Jun. 2007	Interim results	Full year results	Apr. 2008 to Jun. 2008	Interim forecast	Full year forecast
US Dollar (¥/US\$)	121	119	114	105	110	110
Euro (¥/Euro)	163	162	162	164	160	160

(2) Operating indicators (Consolidated)

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009
	Apr. 2007 to Jun. 2007	Interim results	Full year results	Apr. 2008 to Jun. 2008
(prior to amortization of goodwill) Net income per share (yen)	13.37	27.77	59.03	20.87 16.69
Operating income to sales ratio (%)	8.0	9.5	10.0	13.6
Total assets (million yen)	389,394	396,667	394,081	744,591
Net assets (million yen)	248,077	252,211	256,758	556,749
Equity ratio (%)	63.1	62.9	64.5	74.1
Net assets per share (yen)	617.36	627.70	639.69	961.41
ROIC (Return on invested capital)*	2.6	6.3	13.8	4.7

$$* \text{ROIC} (\%) = \frac{\text{Operating income}}{(\text{Fixed assets} + \text{Working capital})} \times 100$$

Calculations for operating income are prior to amortization of goodwill and calculations for fixed assets do not include goodwill

II. Subsidiaries and affiliates

(As of June 30, 2008)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kirin Pharma Company, Ltd.	100.0%	Manufacture and sale of pharmaceuticals, etc.
		Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio-Pharmaceutical Co.,	70.0%	Manufacture and sale and of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology and development of therapeutic antibodies (US Company)
		Kirin Pharma USA, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of anti-body treatment products (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of anti-body treatment products (US)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kirin Pharmaceuticals Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kirin Pharmaceutical (Asia) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong kong)
		Kirin Pharmaceutical Singapore PTE., Ltd.	100.0%	Sales of pharmaceuticals (Singapore)
Kirin Pharmaceutical (Thailand) Co., Ltd.	100.0%	Sales of pharmaceuticals (Thailand)		
Bio-Chemicals	Consolidated subsidiary	DAIICHI FINE CHEMICAL CO., LTD.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US Company)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China Company)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of pharmaceuticals and fine chemicals (US Company)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of pharmaceuticals and fine chemicals (Germany Company)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sale and import/export of pharmaceuticals and fine chemicals (Italy Company)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of pharmaceuticals and fine chemicals (Hong Kong Company)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
		Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods
Kyowa Engineering Co., Ltd.	100.0%	Plant facilities and equipment		
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
		Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.
Food	Consolidated subsidiary	Kyowa Hakko Food Specialties Co., Ltd.	100.0%	Manufacture and sale of seasonings, bakery products, ingredients and other foods
		Kyowa F.D. Foods Co., Ltd.	100.0%	Manufacture and sale of freeze-dried foods
		Ohland Foods Co., Ltd.	100.0%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	100.0%	Import and sale of foods, etc.
	Affiliate accounted for by the equity method	Aji-Nihon Co., Ltd.	46.3%	Manufacture and sale of foods and seasonings, etc.
		Zenmi Foods Inc.	50.0%	Manufacture and sale of seasoning agent extract
Other	Consolidated subsidiary	Miyako Kagaku Co., Ltd.	52.9%	Wholesale sales of pharmaceuticals, chemicals, foods, etc.
		Chiyoda Kaihatsu Co., Ltd.	100.0%	Sale of distribution, insurance, foods etc.
		Kashiwagi Corporation	56.0%	Wholesale sales of chemicals, pharmaceutical products, construction materials, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Changes to the scope of consolidation

Newly consolidated: One company: Kirin Pharma Company, Limited.

III. Net sales by division (items and main products presented on a non-consolidated basis)

*Interim and full year forecasts for the fiscal year ending March 31, 2009 have not changed from those announced on April 28, 2008.

Kyowa Hakko Kogyo Co., Ltd. and Kirin Pharma Company, Limited

Billions of yen, rounded down

Pharmaceuticals division (Non-Consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009			
	Apr. 2007 to Jun. 2007 (A)	Interim results	Full year results	Apr. 2008 to Jun. 2008 (B)	Change (B-A)	Interim forecasts	Full year forecasts
Pharmaceutical division total	31.5	62.9	127.3	54.2	22.7	101.5	194.0
Central nervous system agents							
<i>Depakene</i>	2.6	5.2	10.5	2.7	0.1	5.1	10.3
<i>Topina</i>	--	--	0.1	0.1	0.1	0.4	1.2
Sensory organ agents							
<i>Patanol</i>	0.3	0.8	4.3	0.6	0.3	1.9	5.0
Circulatory organ agents							
<i>Coniel</i>	6.7	13.2	25.4	6.0	(0.7)	11.5	22.8
<i>Inovan + Pre Dopa</i>	1.0	2.0	4.1	0.9	(0.1)	1.8	3.7
<i>Coversyl</i>	--	--	--	1.4	1.4	2.2	4.3
Digestive organ agents							
<i>Nauzelin</i>	1.4	2.6	6.1	1.3	(0.1)	2.5	5.8
Other agents affecting metabolism							
<i>NESP/ESPO</i>	--	--	--	10.2	10.2	23.2	46.8
<i>REGPARA</i>	--	--	--	0.8	0.8	3.1	6.9
Agents relating to blood and body fluids							
<i>Gran/Neu-up</i>	1.1	2.3	4.4	4.5	3.4	9.1	18.2
Anticancer agents							
<i>Farmorubicin + Adriacin</i>	2.2	4.4	8.7	1.9	(0.3)	4.0	7.9
<i>5-FU</i>	0.8	1.7	3.4	0.9	0.1	1.7	3.4
<i>Navelbine</i>	0.8	1.6	3.1	0.8	0.0	1.6	3.3
Antiallergic agents							
<i>Allelock</i>	5.2	9.5	23.3	5.1	(0.1)	10.2	23.3
<i>Celtect</i>	1.1	2.0	4.1	0.9	(0.2)	1.7	3.7
Others							
<i>Durotep</i>	3.7	7.1	13.9	0.0	(3.7)	--	--
Exports and technology out-licensing	4.1	10.3	16.3	15.3	11.2	22.4	29.5

Note 1: Figures for fiscal 2007 are Kyowa Hakko non-consolidated figures and do not include Kirin Pharma. Figures for fiscal 2008 include both non-consolidated Kirin Pharma and non-consolidated Kyowa Hakko.

Note 2: Results based on settlement price on a shipment basis. Forecasts are based on an actual consumption basis.

Note 3: Figures for Gran and Neu-up for the fiscal year ended March 31, 2008 do not include unit sales for Gran produced by Kirin Pharma.

Bio-Chemicals division (Non-consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009			
	Apr. 2007 to Jun. 2007 (A)	Interim results	Full year results	Apr. 2008 to Jun. 2008 (B)	Change (B-A)	Interim forecasts	Full year forecasts
Bio-chemical division total	13.3	26.7	55.1	14.9	1.6	27.0	55.5
Pharmaceuticals / Industrial raw materials							
Amino acids	4.7	9.6	20.1	5.3	0.6	9.9	20.1
Nucleic acids and vitamins	1.4	2.7	5.1	1.6	0.2	2.3	4.7
Health care products	1.9	3.9	7.6	2.1	0.2	4.3	8.6
Agrochemicals, livestock and fisheries products	0.8	1.6	3.8	0.8	0.0	1.7	3.9
Alcohol	2.2	4.5	9.4	2.4	0.2	4.4	9.4

Note 1: As a result of the separation of the Company's bio-chemical division in October 2008, figures as of the second half of the fiscal year ending March 31, 2009 are those of Kyowa Hakko Bio-chemical

Billions of yen, rounded down

Chemicals division (Non-consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009			
	Apr. 2007 to Jun. 2007 (A)	Interim results	Full year results	Apr. 2008 to Jun. 2008 (B)	Change (B-A)	Interim forecasts	Full year forecasts
Chemical division total (Kyowa Hakko Chemical non- consolidated)	23.6	51.0	107.9	25.1	1.5	55.0	116.0
Solvents	11.5	24.3	50.3	11.9	0.4	25.5	52.0
Raw materials for plasticizers	6.6	15.4	33.4	7.4	0.8	17.5	37.5
Specialty chemicals	4.4	8.7	19.3	4.8	0.4	9.5	21.5

Billions of yen, rounded down

Food division (Non-consolidated) (Kyowa Hakko Food Specialties Co., Ltd.)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009			
	Apr. 2007 to Jun. 2007 (A)	Interim results	Full year results	Apr. 2008 to Jun. 2008 (B)	Change (B-A)	Interim forecasts	Full year forecasts
Food division total	9.2	18.5	38.4	9.4	0.2	18.6	38.5
Natural seasonings	3.6	7.4	15.3	3.6	0.0	7.7	15.8
Umami seasonings	1.0	2.0	4.4	1.1	0.1	2.1	4.3
Bakery ingredients and products	2.3	4.6	8.8	2.1	(0.2)	4.3	8.7
Processed foods	1.5	3.1	7.0	1.6	0.1	3.0	6.7

R&D PIPELINE

KYOWA HAKKO

July 31st, 2008

Category	Code Name Product Name	Generic Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
			Japan	Other countries				
Cancer	KW-2246	Fentanyl citrate	Phase		Cancer pain	Sublingual tablet	Licensed from Orexo.	
	KW-0761		Phase		Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody (*) (Rights for development and sale, except cancer area, and except in Japan, China, Korea and Taiwan were given to U.S company Amgen)
	KW-2449			Phase in USA	Cancer	Oral	Developed In-house	
	KW-2478			Phase in Europe	Cancer	Injection	Developed In-house	
	ARQ 197		Phase		Cancer	Oral	Licensed from ArQule	
Allergy	KW-4679 ALLELOCK	Olopatadine Hydrochloride		Preparation for filing in China	Antiallergic	Oral	Developed In-house	Launched in Japan
CNS	KW-6002	Istradefylline	Phase b	Filed in USA Apr/2007	Parkinson's disease	Oral	Developed In-house	Clinical trials for Mono-Therapy : Phase a, in Japan (Currently on sale in Japan)
	KW-6500	Apomorphine Hydrochloride	Phase		Parkinson's disease	Injection	Licensed from Britannia Pharma.	
Cardiovascular	KW-3049 CONIEL	Benidipine Hydrochloride		Filed in China Jul/2007	Angina	Oral	Developed In-house	Launched for Hypertension in China in Dec 2004
Others	Z-206 ASACOL	Mesalazine	Phase		Inflammatory bowel disease (Crohn's disease)	Oral (pH depend controlled-release formulation)	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma.
	KW-7158		Phase a		Bowel disease (Irritable bowel syndrome)	Oral	Developed In-house	The development program of KW-7158 (Phase a clinical trials) for Overactive bladder/Urinary incontinence was discontinued in Sep 2006.
	KW-3357	Antithrombin	Phase		Blood coagulation factor inhibitor (Disseminated intravascular coagulation)	Injection	Developed In-house	Recombinant antithrombin product

(*) KW-0761 is out licensed to Amgen Inc. on March 6th,2008, with an exclusive right to develop and commercialize KW-0761 worldwide, except in Japan, Korea, China and Taiwan. Kyowa Hakko has retained the development and commercialization rights in these countries. (Amgen has initially acquired the rights in all non-oncology indications, and Kyowa Hakko will continue its development activities in oncology until the completion of Phase a. At that time, Amgen may elect to reimburse Kyowa Hakko for its oncology-related development costs, expand its license to include oncology and assume the development and commercialization of KW-0761 in oncology settings.)

KIRIN PHARMA

Category	Code Name Product Name	Generic Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
			Japan	Other countries				
Hematology/Cancer	KRN321 NESP	Darbepoetin Alfa	Phase		Anemia (After chemotherapy for cancer)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein. Sales for anemia of CKD patients on dialysis were launched in Japan in July 2007.
	KRN125	Pegfilgrastim	Phase		Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF
	KRN654	Hydrochloric acid agrylin	Phase /		Essential thrombocythemia	Oral	Licensed from Shire.	
	KRN330			Phase in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
	AGS-003			Phase in USA and Canada	Renal cell carcinoma	Injection	Developed with Argos.	Dendritic cell-based immunotherapeutics
	AGS-004			Phase in USA	HIV	Injection	Developed with Argos.	Dendritic cell-based immunotherapeutics
Kidney	KRN321NESP	Darbepoetin Alfa	Phase	Phase in China	Anemia (for CKD patients not on dialysis)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein. Sales for anemia of CKD patients on dialysis were launched in Japan in July 2007.
	PB94 PHOSBLOCK/ RENAGEL	Sevelamer Hydrochloride		Filed in China Jun/2008	Hyperphosphatemia	Oral	Licensed from Chugai.	Launched in Japan
Others	NU206			Phase	Inflammatory bowel disease	Injection	Developed with Nuvelo.	

(Note) Application for NESP, manufactured by Kirin Pharma (Japan), has been filed in Korea, Taiwan and Thailand.
Aranesp, manufactured by Amgen Inc. (U.S.), is currently being marketed in Hong Kong and Singapore. It will be switched to NESP in the near future.
In other ASEAN countries, an NDA will be filed as NESP.

(Note) Although not included in this table, in Vietnam, an application for NDA of Pegfilgrastim(long acting G-CSF) has been filed for neutropenia and, in the Philippines, an NDA of Filgrastim(G-CSF) has been filed for neutropenia.

Updated since Apr 28th, 2008 (Area, Stage, Filed, Approved, Launched etc.)
New indication